Opinion

Video

Surgical Considerations and Patient Selection for PDS With Ranibizumab

Dr. Margaret Chang details the facility requirements for PDS implantation, the specialized training surgeons need, and crucial factors to consider for the surgical implantation of PDS.

  1. What facilities are required to implant the device, and what specific training does a surgeon need?
  2. What are the key considerations for the surgical implantation and subsequent refilling of the PDS?
  3. What are the major adverse effects associated with the PDS, and which patients are not suitable candidates for this delivery system?
  4. How does the PDS with ranibizumab fit into the treatment landscape that also includes highly durable agents such as faricimab and high-dose aflibercept?

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
© 2025 MJH Life Sciences

All rights reserved.